Navigation Links
Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
Date:9/16/2010

WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Alere Inc. (NYSE: ALR) announced today that, in connection with its previously announced private placement of senior subordinated notes due 2018, it entered into a purchase agreement with the initial purchasers of the notes on September 15, 2010.  The size of the offering was increased from $350.0 million to $400.0 million.  The notes have a coupon of 8.625% and are being offered at 100.0% of the aggregate principal amount of the notes.  Alere expects to complete the offering on or about September 21, 2010 and intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The notes are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and outside the United States in compliance with Regulation S under the Securities Act.  The notes are not being registered under the Securities Act.  Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing of the completion of the offering and the use of proceeds. These statements reflect Alere's current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market and economic conditions and closing conditions. Alere undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Alere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverness Medical Innovations Changes Name to Alere
2. Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results
3. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
4. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... on the research, distribution, and marketing of pharmaceutical drug ... by patent protection and expiration. Additionally, these firms typically ... sector as a whole. Up for review this morning ... Synergy Pharmaceuticals Inc. (NASDAQ: SGYP ), Pernix ...
(Date:12/8/2016)... , Dec. 8, 2016 Spotlight ... advancing technologies designed to address rare, emerging and ... Chitra Edwin , Ph.D., RAC, as Senior Vice ... will provide leadership for all U.S. and international ... preparation of regulatory submissions, serving as the primary ...
(Date:12/7/2016)... "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by PNS ... in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... on Lantus expired in 2014. Lantus is the brand name for ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... The Compretta ... commercial and residential clients in and around the Hancock County area, is announcing the ... Hancock County Food Pantry. , The Hancock County Food Pantry has worked for more ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in ... MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs ... where and when it’s needed. , A 2’ x 4’ model features ...
Breaking Medicine News(10 mins):